IP Library Granted Patent US 8,871,213
Granted Patent B2
US 8,871,213 · App. 13/060,653 · Granted Oct 28, 2014

Prevention, treatment and diagnosis of

Inventors: Eric Charles Reynolds (Melbourne, AU); Neil Martin O'Brien Simpson (Melbourne, AU); Keith J Cross (Melbourne, AU); Nada Slakeski (Melbourne, AU)
Assignee: Oral Health Australia Pty Ltd
C07K16/1257A61K2039/53C07K14/195C07K2317/34G01N33/56955A61K2039/55566A61K39/0216
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,213
App. No.
13/060,653
Granted
Oct 28, 2014
Kind
B2
Abstract

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

Claims (33)

1. A chimeric or fusion protein for inducing an immune response to P. gingivalis , the protein comprising a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein:

(A) said first peptide comprises a region of a P. gingivalis trypsin-like enzyme selected from the group consisting of the amino acid sequence that is the same as, or at least 90% homologous to, the sequence shown in any one of SEQ ID NOs: 1-34; and

(B) said second peptide or polypeptide comprises an adhesin domain of P. gingivalis , or fragment thereof, selected from the group consisting of:

(i) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of an adhesin domain of the Lys-X-proteinase of P. gingivalis shown in any one of SEQ ID NOs: 35-37 and 40-43; and

(ii) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of an adhesin domain of the Arg-X-proteinase of P. gingivalis shown in any one of SEQ ID NOs: 38-39 and 44-46;

(iii) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of a HagA adhesin domain of P. gingivalis shown in any one of SEQ ID NOs: 80-82; and

(iv) the amino acid sequence that is the same as or at least 90% homologous to the sequence shown in any one of SEQ ID NOs: 69-79 and 83 to 85.

2. The chimeric or fusion protein according to claim 1 , wherein said first peptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 3-34 and sequences at least 90% homologous thereto.

3. The chimeric or fusion protein according to claim 1 , wherein said second peptide or polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 35-39 and sequences at least 90% homologous thereto.

4. The chimeric or fusion protein according to claim 1 , wherein:

(a) said first peptide comprises the amino acid sequence that is the same as or at least 90% homologous to the sequence shown in any one of SEQ ID NOs: 27-30 and said second peptide or polypeptide comprises the amino sequence that is the same as or at least 90% homologous to the sequence shown in any one of SEQ ID NOs: 36-37; or

(b) said first peptide comprises the amino acid sequence that is the same as or at least 90% homologous to the sequence shown in any one of SEQ ID NOs: 31-34 and said second peptide or polypeptide comprises a sequence that is the same as or at least 90% homologous to SEQ ID NO:39.

5. A chimeric or fusion protein according to claim 1 , wherein the C-terminal residue of said first peptide is covalently linked directly or through a linker that is either (i) up to 15 amino acids in length, or (ii) less than 5 amino acids in length, to either (a) the N-terminal residue or (b) the C-terminal residue of said second peptide or polypeptide.

6. A chimeric or fusion protein according to claim 1 , wherein the N-terminal residue of said first peptide is covalently linked directly or through a linker that is either (i) up to 15 amino acids in length, or (ii) less than 5 amino acids in length, to either (a) the N-terminal residue or (b) the C-terminal residue of said second peptide or polypeptide.

7. A composition comprising a chimeric or fusion protein according to claim 1 .

8. The composition according to claim 7 , further comprising an adjuvant.

9. A method of preventing or reducing the incidence or severity of a P. gingivalis -related condition or disease in a subject, comprising administering to the subject a chimeric or fusion protein of claim 1 .

10. A method for the diagnosis or monitoring of a P. gingivalis -related condition or disease in a subject, which comprises assaying a biological sample from said subject with the chimeric or fusion protein of claim 1 to detect anti- P. gingivalis antibodies.

11. A chimeric or fusion protein according to claim 1 wherein the second peptide or polypeptide comprises or consists of the sequence shown in one or more of SEQ ID NOs: 69 to 79 or one or more of SEQ ID NOs: 83 to 85.

12. A chimeric or fusion protein according to claim 11 wherein the first peptide comprises or consists of the sequence shown in one of more of SEQ ID NOs: 3 to 26.

13. The chimeric or fusion protein according to claim 1 , comprising:

(A) a first peptide with the sequence from a P. gingivalis trypsin-like enzyme selected from the group consisting of KAS1 (SEQ ID NO: 27), KAS2 (SEQ ID NO: 28), KAS3 (SEQ ID NO: 29), PAS1K (SEQ ID NO: 30), RAS1 (SEQ ID NO: 31), RAS2 (SEQ ID NO: 32), RAS3 (SEQ ID NO: 33), and PAS1R (SEQ ID NO: 34), and

(B) a second peptide or polypeptide comprising an adhesin domain of P. gingivalis , or fragment thereof, wherein said second polypeptide has the sequence selected from the group consisting of (i) KA1 (SEQ ID NO: 35), KA2 (SEQ ID NO: 40), KA3 (SEQ ID NO: 41), KA4 (SEQ ID NO: 42), KA5 (SEQ ID NO: 43), RA1 (SEQ ID NO: 38), RA2 (SEQ ID NO: 44), RA3 (SEQ ID NO: 45), RA4 (SEQ ID NO: 46), HA1 (SEQ ID NO: 80), HA1* (SEQ ID NO: 81), HA1** (SEQ ID NO: 82), or (ii) SEQ ID NOs.: 69-79, or (iii) SEQ ID NOs.: 83-85.

14. A chimeric or fusion protein for inducing an immune response to P. gingivalis , comprising KAS4 (SEQ ID NO: 64), KAS3 (SEQ ID NO: 29) KAS5 (SEQ ID NO: 65), and KAS6 (SEQ ID NO: 66).

15. A chimeric or fusion protein for inducing an immune response to P. gingivalis , comprising

at least two amino acid sequences that are the same as, or at least 90% homologous to the sequence from a P. gingivalis trypsin-like enzyme selected from the group consisting of KAS1 (SEQ ID NO: 27), KAS2 (SEQ ID NO: 28), KAS3 (SEQ ID NO: 29), PAS1K (SEQ ID NO: 30), RAS1 (SEQ ID NO: 31), RAS2 (SEQ ID NO: 32), RAS3 (SEQ ID NO: 33), and PAS1R (SEQ ID NO: 34); and

at least one sequence that comprises an adhesin domain of P. gingivalis , or fragment thereof, and that has the sequence selected from:

(i) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of an adhesin domain of the Lys-X-proteinase of P. gingivalis shown in any one of SEQ ID NOs: 35-37 and 40-43; and

(ii) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of an adhesin domain of the Arg-X-proteinase of P. gingivalis shown in any one of SEQ ID NOs: 38-39 and 44-46;

(iii) the amino acid sequence that is the same as, or at least 90% homologous to the sequence of a HagA adhesin domain of P. gingivalis shown in any one of SEQ ID NOs: 80-82; and

(iv) the amino acid sequence that is the same as or at least 90% homologous to the sequence shown in any one of SEQ ID NOs: 69-79 and 83 to 85.

16. The chimeric or fusion protein according to claim 4 wherein said first peptide comprises the sequence that is the same as or at least 90% homologous to the sequence shown in SEQ ID NO:28 and said second peptide or polypeptide comprises the sequence that is the same as or at least 90% homologous to the sequence shown in SEQ ID NO: 37.

17. The chimeric or fusion protein according to claim 4 wherein said first peptide comprises the sequence that is the same as or at least 90% homologous to the sequence shown in SEQ ID NO:27 and said second peptide or polypeptide comprises the sequence that is the same as or at least 90% homologous to the sequence shown in SEQ ID NO:36.

Assignments (2)
RE-RECORD TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL/FRAME 026260/0541. Recorded Jul 28, 2011
From: REYNOLDS, ERIC CHARLES; O'BRIEN SIMPSON, NEIL MARTIN; CROSS, KEITH J; SLAKESKI, NADA
To: ORAL HEALTH AUSTRALIA PTY LTD
Reel/Frame 026698/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2011
From: REYNOLDS, ERIC CHARLES; O'BRIEN SIMPSON, NEIL MARTIN; CROSS, KEITH J.; SLAKESKI, NADA
To: ORAL HEALTH AUSTRALIA PTY LTD.
Reel/Frame 026260/0541 →
Priority Claims (3)
AU 2008904476 · Aug 29, 2008 · national
AU 2008905483 · Oct 23, 2008 · national
AU 2009903052 · Jun 30, 2009 · national
Continuity (2)
Provisional Application 61151132 · Feb 9, 2009
Related Publication 20110280880A1 · Nov 17, 2011